Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Disease-resistant pigs latest win for gene editing technology

Published 2015-12-08, 07:12 a/m
© Reuters.  Disease-resistant pigs latest win for gene editing technology
GNS
-

By Ben Hirschler
LONDON, Dec 8 (Reuters) - A British animal genetics firm,
working with U.S. scientists, has bred the world's first pigs
resistant to a common viral disease, using the hot new
technology of gene editing.
Genus GENS.L , which supplies pig and bull semen to farmers
worldwide, said on Tuesday it had worked with the University of
Missouri to develop pigs resistant to Porcine Reproductive and
Respiratory Syndrome Virus (PRRSv).
The condition, also known as blue-ear disease, can be fatal
as it affects the animals' immune system and costs farmers
hundreds of millions of dollars a year. There is no cure.
By using precise gene editing, the team from the University
of Missouri was able to breed pigs that do not produce a
specific protein necessary for the virus to spread in the
animals. Their research was published in journal Nature
Biotechnology.
Early-stage studies showed the new PRRSv resistant pigs,
when exposed to the virus, did not get sick and continued to
gain weight normally.
The development of these resistant pigs is further proof of
the power of gene editing, which is taking the biotech industry
by storm. Genus Chief Scientific Officer Jonathan Lightner said
it was "a potential game-changer for the pork industry".
Editing the genes of living organisms holds out great
promise for treating diseases and improving agricultural crops
and animal species. But when applied to humans it could also be
used to create "designer babies", prompting critics to call for
a global ban on genetic modification of human embryos.
The technology allows scientists to edit genes by using
biological "scissors" that operate a bit like a word-processing
programme that can find and replace selected stretches of DNA.
It has been put to work in laboratories around the world,
even as the ethical and safety issues it raises are fiercely
debated.
An international summit on human gene editing in Washington
last week urged caution on human gene editing but said editing
genes in human embryos was permissible for research purposes.

The work on Genus's gene-edited pigs is still at an early
stage and Lightner said there were several critical challenges
ahead to fully develop and commercialise the technology.
Liberum analyst Sophie Jourdier said commercialisation would
likely take five years or more but the new resistant pig line
would add to Genus's long-term growth prospects, given the
economic importance of PRRSv.
PRRSv affects millions of pigs and costs the swine industry
around $700 million a year in the United States and 1.5 billion
euros ($1.6 billion) in Europe, according to a 2011 Iowa State
University study cited by Genus.

($1 = 0.9211 euros)

(Editing by David Evans)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.